Dawson, Amy
Zarou, Martha M. http://orcid.org/0000-0003-0152-1599
Prasad, Bodhayan http://orcid.org/0000-0002-7383-2460
Bittencourt-Silvestre, Joana
Zerbst, Désirée
Himonas, Ekaterini http://orcid.org/0000-0002-5188-8930
Hsieh, Ya-Ching
van Loon, Isabel
Blanco, Giovanny Rodriguez
Ianniciello, Angela
Kerekes, Zsombor
Krishnan, Vaidehi http://orcid.org/0000-0002-5028-6567
Agarwal, Puneet http://orcid.org/0000-0003-1688-3840
Almasoudi, Hassan
McCluskey, Laura
Hopcroft, Lisa E. M. http://orcid.org/0000-0002-7022-1322
Scott, Mary T. http://orcid.org/0000-0002-7177-6960
Baquero, Pablo
Dunn, Karen http://orcid.org/0000-0002-6532-970X
Vetrie, David http://orcid.org/0000-0003-2075-4662
Copland, Mhairi http://orcid.org/0000-0002-7655-016X
Bhatia, Ravi http://orcid.org/0000-0001-5740-2316
Coffelt, Seth B. http://orcid.org/0000-0003-2257-2862
Tiong, Ong Sin http://orcid.org/0000-0001-9460-3483
Wheadon, Helen http://orcid.org/0000-0001-9902-3170
Zanivan, Sara
Kirschner, Kristina http://orcid.org/0000-0001-7607-8670
Helgason, G. Vignir http://orcid.org/0000-0003-1616-132X
Funding for this research was provided by:
Kay Kendall Leukaemia Fund (KKL698)
Cancer Research UK (A29754, A29800)
Article History
Received: 29 April 2022
Accepted: 25 January 2024
First Online: 5 February 2024
Competing interests
: M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals. All other authors declare no competing interests.